Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Other Residual Products (8-K Schedule) — U.S. by Quarter
Other Residual Products (8-K Schedule) — U.S. ($M) ($M)
Amgen Other Residual Products (8-K Schedule) — U.S.: $304M in Q2 2026, up 9.4% from a year earlier.
Latest, Q2 2026
304
Period ended Jun 30, 2026
Change on a year earlier
+9.4%
278 in Q2 2025
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
“|| Other products (2) | 304 | 47 | 351 | 334 | 5%”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Product Sales Detail Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen Other Residual Products (8-K Schedule) — U.S. ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-other-8k-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.